Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ ‐Induced Diabetic Rats via AMPK / JAK – STAT Pathway Crosstalk
Endocrinology, Diabetes & Metabolism · 2025-09 · 8 (5)
DOI: 10.1002/edm2.70101 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 03.09.2025. Verfasst von Mostafa Allahyari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Experimental, Azetidines, Sulfonamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Golestan University of Medical Sciences.
Abstract (Originalsprache)
Background
Chronic inflammation is a critical factor contributing to diabetes complications. Baricitinib inhibits JAK–STAT signalling, which can contribute to an anti‐inflammatory effect. Similarly, metformin demonstrates anti‐inflammatory properties by activating the AMPK–SIRT pathway and suppressing the NF‐ᴋB signalling pathway. Here, we explored the effects of the coadministration of metformin and baricitinib in diabetic rats.
Methods
Streptozotocin (40 mg/kg body weight) was administered to rats to develop diabetes after 2 weeks of 10% fructose solution consumption. The rats were treated with baricitinib (0.5, 2.5 and 5 mg/kg) and 150 mg/kg metformin for 1 month. A dose of 0.5 mg/kg baricitinib was chosen for combination therapy with metformin. Key Findings Baricitinib induced significant weight loss at all three doses ( p ≤ 0.05) and significantly increased lipid profile parameters in comparison to the diabetic control group ( p ≤ 0.05). Pancreatic NF‐ᴋB levels and HOMA‐IR were meaningfully reduced in all treatment groups ( p ≤ 0.01). Metformin and combination therapy significantly reduced serum TNF‐α levels ( p ≤ 0.05). Furthermore, baricitinib at different doses and combination therapy significantly elevated serum IL‐10 levels ( p ≤ 0.05). Additionally, combination therapy significantly upregulated the liver expression of NF‐ᴋB, SOCS1, SOCS3, AMPK and SIRT‐1 ( p ≤ 0.01).
Conclusion
Our results suggest that the coadministration of metformin with baricitinib reduces insulin resistance, improves histopathological alterations in the liver and pancreatic islet cells and counteracts the adverse effects of baricitinib on the lipid profile in diabetic rats. These findings hold particular significance for patients undergoing baricitinib treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
- Department of Biochemistry and Biophysics, Golestan University of Medical Sciences, Gorgan, Iran.
- Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
ORCID-Profile: AbdolJalal Marjani, Marie Saghaeian Jazi
Förderung
- Golestan University of Medical Sciences
Zitieren
APA
Allahyari, M., Marjani, A., Jazi, M. S., & Jahanshahi, M. (2025). Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ ‐Induced Diabetic Rats via AMPK / JAK – STAT Pathway Crosstalk. Endocrinology, Diabetes & Metabolism, 8(5). https://doi.org/10.1002/edm2.70101
Vancouver
Allahyari M, Marjani A, Jazi MS, Jahanshahi M. Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ ‐Induced Diabetic Rats via AMPK / JAK – STAT Pathway Crosstalk. Endocrinology, Diabetes & Metabolism. 2025;8(5). doi:10.1002/edm2.70101
BibTeX
@article{Allahyari2025,
author = {Allahyari, Mostafa and Marjani, AbdolJalal and Jazi, Marie Saghaeian and Jahanshahi, Mehrdad},
title = {Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ ‐Induced Diabetic Rats via AMPK / JAK – STAT Pathway Crosstalk},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {5},
doi = {10.1002/edm2.70101}
}
EUVIMED